- Home
- ENGN vs SLN Comparison
ENGN vs SLN Comparison
Compare ENGN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENGN | SLN |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 318.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ENGN | SLN |
|---|---|---|
| Price | $8.42 | $6.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $22.71 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 528.5K | 314.1K |
| Earning Date | 12-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $25,830,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 40.39 |
| 52 Week Low | $2.65 | $1.97 |
| 52 Week High | $11.14 | $8.08 |
Technical Indicators
Market Signals| Indicator | ENGN | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 50.57 |
| Support Level | $7.77 | $5.95 |
| Resistance Level | $9.14 | $6.60 |
| Average True Range (ATR) | 0.60 | 0.53 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 58.43 | 41.33 |
Price Performance
Historical ComparisonAbout ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.